Vanguard Capital Management
VIR icon

Vanguard Capital Management’s Vir Biotechnology VIR Stock Holding History

Vanguard Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65.1M Buy
6,388,775
+1,006,672
+19% +$9.58M ﹤0.01% 1793
2026
Q1 		$48.2M Buy
+5,382,103
New +$42.9M ﹤0.01% 1871

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management's VIR Position: Q2 2026 in Review

Vanguard Capital Management increased its Vir Biotechnology (VIR) stake by 19% in Q2 2026, buying an estimated $9.58M and bringing the position to 6,388,775 shares worth $65.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1793.

Vanguard Capital Management first reported a position in VIR in Q1 2026 and has held it in 2 quarters since. 236 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Vanguard Capital Management held 6,388,775 shares of Vir Biotechnology worth $65.1M as of Q2 2026.
  • Vanguard Capital Management bought 1,006,672 Vir Biotechnology shares in Q2 2026, an estimated $9.58M.
  • Vir Biotechnology made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1793 holding.
  • Vanguard Capital Management first reported a position in Vir Biotechnology in Q1 2026 and has held it in 2 quarters since.
  • 236 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.